• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

    2/14/24 5:02:01 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email
    SC 13G/A 1 d628447dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Wave Life Sciences Ltd.

    (Name of Issuer)

    $0 Par Value Ordinary Shares

    (Title of Class of Securities)

    Y95308105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. Y95308105

     

     1   

     NAMES OF REPORTING PERSONS

     

     Maverick Capital, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     8,447,804

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     8,447,804

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     8,447,804

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. Y95308105

     

     1   

     NAMES OF REPORTING PERSONS

     

     Maverick Capital Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     8,447,804

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     8,447,804

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     8,447,804

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     HC


    CUSIP No. Y95308105

     

     1   

     NAMES OF REPORTING PERSONS

     

     Lee S. Ainslie III

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     8,447,804

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     8,447,804

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     8,447,804

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    Item 1(a).

    Name of Issuer:

    Wave Life Sciences Ltd.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    7 Straits View #12-00, Marina One East Tower

    Singapore

     

    Item 2(a).

    Names of Persons Filing:

    This Schedule 13G (the “Schedule 13G”) is being filed on behalf of each of the following persons (each, a “Reporting Person”):

     

      (i)

    Maverick Capital, Ltd.;

     

      (ii)

    Maverick Capital Management, LLC; and

     

      (iii)

    Lee S. Ainslie III (“Mr. Ainslie”).

    The Schedule 13G relates to Ordinary Shares (as defined herein) held for the accounts of Maverick Capital, Ltd.’s clients.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of (i) Maverick Capital, Ltd. and Maverick Capital Management, LLC is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.

     

    Item 2(c).

    Citizenship:

     

      (i)

    Maverick Capital, Ltd. is a Texas limited partnership;

     

      (ii)

    Maverick Capital Management, LLC is a Texas limited liability company; and

     

      (iii)

    Mr. Ainslie is a citizen of the United States.

     

    Item 2(d).

    Title of Class of Securities:

    $0 Par Value Ordinary Shares (“Ordinary Shares”)

     

    Item 2(e).

    CUSIP Number:

    Y95308105


    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)   

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)   

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)   

    ☒   An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

    (f)   

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

    (g)   

    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

    (h)   

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)   

    ☐   A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)   

    ☐   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

    (k)   

    ☐   Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    Item 4.

    Ownership.

    Ownership as of December 31, 2023 is incorporated by reference to items (5) – (9) and (11) of the cover page of the Reporting Person. The ownership percentages are based on 122,011,901 outstanding Ordinary Shares as reported in the Issuer’s Prospectus Supplement filed on December 8, 2023, and after giving effect to the exercise of the underwriters’ option to purchase additional Ordinary Shares in connection with the Issuer’s offering, as reported in the Issuer’s Current Report on Form 8-K filed on January 4, 2024.

    Maverick Capital, Ltd. is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the Ordinary Shares which are the subject of this filing through the investment discretion it exercises over its clients’ accounts. Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd. Mr. Ainslie is the manager of Maverick Capital Management, LLC.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.


    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    MAVERICK CAPITAL, LTD.
    By: Maverick Capital Management, LLC, its General Partner
    By: Lee S. Ainslie III, Manager
    By:   /s/ Trevor Wiessmann
      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018
    MAVERICK CAPITAL MANAGEMENT, LLC
    By:   Lee S. Ainslie III, Manager
    By:   /s/ Trevor Wiessmann
      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018
    LEE S. AINSLIE III
    By:   /s/ Trevor Wiessmann
      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018


    EXHIBIT INDEX

     

    A.

    Joint Filing Agreement, dated February 14, 2024, by and among Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III.

     

    B.

    Power of Attorney, Lee S. Ainslie III, dated March 15, 2018.

    Get the next $WVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    10/20/2025$18.00Overweight
    Wells Fargo
    8/4/2025$19.00Buy
    Canaccord Genuity
    7/28/2025$24.00Outperform
    Oppenheimer
    7/16/2025$16.00Buy
    Citigroup
    6/11/2025$14.00Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    More analyst ratings

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wave Life Sciences upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Wave Life Sciences from Sector Perform to Outperform and set a new price target of $27.00

    12/9/25 8:38:23 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Wave Life Sciences with a new price target

    Wells Fargo initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $18.00

    10/20/25 8:06:13 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Wave Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $19.00

    8/4/25 8:22:27 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

    CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health ("Wave" or "Wave Life Sciences"), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share ex

    12/9/25 9:50:00 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

    CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health ("Wave" or "Wave Life Sciences"), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underly

    12/8/25 4:01:00 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turnarounds and 18,000% Growth

    DENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Markets opened the week with a burst of small-cap energy as several niche innovators, spanning luxury foods, next-gen biomaterials, and RNA therapeutics, delivered updates that injected fresh optimism into the narrative before the opening bell: Top Wealth Group (NASDAQ:TWG) Signals a Turnaround Year Top Wealth Group, the premium caviar and fine-wine supplier, set an upbeat tone after projecting no less than $4 million in net profit for FY2025, marking a powerful reversal from last year's $2 million loss. Management attributed the rebound to operational improvements realized throughout 2024. CEO Kim Kwan Kings, Wong said, "We have worked diligent

    12/8/25 9:43:58 AM ET
    $PAVS
    $TWG
    $WVE
    Medicinal Chemicals and Botanical Products
    Health Care
    Packaged Foods
    Consumer Staples

    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    10/1/24 5:54:39 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    1/30/24 4:39:08 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rawcliffe Adrian sold $109,421 worth of Ordinary Shares (16,115 units at $6.79), decreasing direct ownership by 56% to 12,700 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 9:00:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bolno Paul sold $2,194,810 worth of Ordinary Shares (217,351 units at $10.10), decreasing direct ownership by 64% to 121,000 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    8/26/25 9:40:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    SEC Filings

    View All

    SEC Form 144 filed by Wave Life Sciences Ltd.

    144 - Wave Life Sciences Ltd. (0001631574) (Subject)

    12/8/25 7:08:31 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Wave Life Sciences Ltd.

    424B5 - Wave Life Sciences Ltd. (0001631574) (Filer)

    12/8/25 5:04:34 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Wave Life Sciences Ltd.

    144 - Wave Life Sciences Ltd. (0001631574) (Subject)

    12/8/25 4:35:13 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Leadership Updates

    Live Leadership Updates

    View All

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

    5/9/24 7:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

    BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

    3/21/22 7:05:00 AM ET
    $ATHA
    $WVE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

    SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    10/1/24 5:47:15 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

    Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measur

    12/8/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

    CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave's proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. A webcast of the conference call can be accessed by visiting "Investor Events" on the investor relations sec

    12/7/25 4:00:00 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

    WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models  Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to recapitulate the MZ phenotype with WVE-006, GalNAc-RNA editing oligonucleotide, in RestorAATion-2 trial: AAT protein exceeded 20 µM during an acute phase response, basal AAT levels reached 13 µM, wi

    11/10/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care